NEXI's Business Model
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Sector & Industry | Healthcare / Biotechnology |
Website | https://www.neximmune.com |
CEO (Chief Executive Officer) | John Trainer |
Number of Employees | |
IPO date | February 12, 2021 |
NEXI Latest News
|
|
|
|
|
Contact | |
---|---|
Country | US |
Address | 9119 Gaither Road |
City | Gaithersburg |
State | MD |
Phone | 301 825 9810 |
Zip Code | 20877 |
Other Identifiers | |
CIK | 0001538210 |
ISIN | US65344D2080 |
CUSIP | 65344D109 |
Open | 0.0001 |
Previous Close | 0.0001 |
Volume | 500 |
Average Volume | 283 |
Day’s Range | 0.0001 – 0.0001 |
52 Week Range | 0.0001-2.95 |
MA (50) | 0.0001 |
MA (200) | 0.10245 |
Market Cap | 139 |
Shares Out. | 1.39 Mil. |
Earnings Date | Aug 05, 2025 |
Beta | |
Last Dividend | |
EPS | |
PE | |